Osang Healthcare Co (036220) Fair Value & Analysis
Healthcare · KR · Market cap 82.2B KRW
Fair value as of: Jul 20, 2026
From 14 valuation models · updated 21 days ago
Share price +23.6% over the past month.
A solid business, but screening 26% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (6,995 KRW). The favourable scenario is already priced in.
- Solid but not exceptional quality (55/100) and above fair value, neither a clear bargain nor a standout compounder.
- A fairly wide model range (2,840 KRW to 6,995 KRW) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 20, 2026.
How to read this chart
60‑month range 2,048 KRW – 27,578 KRW · fair‑value band 2,840 KRW – 6,995 KRW · the 7,290 KRW price screens above the 5,381 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 20, 2026.
Analysis
Osang Healthcare Co (036220) currently trades at 7,290 KRW, while our model-based Fair Value estimate is 5,381 KRW, implying the stock looks roughly 26.2% overvalued today. The Quality Score stands at 55/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).
Over the trailing twelve months, Osang Healthcare Co generated revenue of 119B KRW at a net margin of -3.7%. Revenue declined 28.8% year over year. It earns a return on equity of -1.6%. Net debt stands at 22.3B KRW. Fundamentals as of Jul 20, 2026
Our scenario range runs from 2,840 KRW (bear case) to 6,995 KRW (bull case); at 7,290 KRW, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 69% below its 52-week high and 23% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -26% fair-value upside, at -26%, 036220 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 14 models by family
Widest divergence: Asset-Based (13,490 KRW) versus Economic Profit (906.47 KRW). Highest evidence: Residual Income (76).
Notify me when 036220 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 20, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 56 · Market factors (momentum, volatility) 23
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Osang Healthcare Co.,Ltd researches, develops, and sells various diagnostic biosensors in South Korea and internationally. The company offers diagnostic biosensors for blood glucose, hemoglobin A1c, cholesterol, immuno diagnosis, molecular diagnosis, and others. It also exports its products to approximately 110 countries worldwide.
Full company description
Osang Healthcare Co.,Ltd researches, develops, and sells various diagnostic biosensors in South Korea and internationally. The company offers diagnostic biosensors for blood glucose, hemoglobin A1c, cholesterol, immuno diagnosis, molecular diagnosis, and others. It also exports its products to approximately 110 countries worldwide. The company was formerly known as Infopia Co., Ltd. and changed its name to Osang Healthcare Co.,Ltd in April 2017. Osang Healthcare Co.,Ltd was founded in 1996 and is headquartered in Anyang-si, South Korea.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Osang Healthcare Co reported revenue of 129B KRW in FY2025 versus 132B KRW in FY2021, a compound −0.7%/yr. Reported net income was 3.1B KRW in FY2025, compounding +20.8%/yr from FY2021.
036220 screens 26% overvalued. Compare with Abbott Laboratories, →
Peer Group
Medical Devices · 352 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Devices median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 20, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $100.68 | $74.79 | -26% |
| Stryker Corporation SYK | $316.44 | $186.28 | -41% |
| Medtronic plc MDT | $83.56 | $65.57 | -22% |
| Boston Scientific Corporation BSX | $43.04 | $38.44 | -11% |
| Edwards Lifesciences Corporation EW | $85.73 | $41.02 | -52% |
| Siemens Healthineers AG SHL | €34.59 | €33.87 | -2% |
| DexCom, Inc DXCM | $74.96 | $38.95 | -48% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥149.43 | ¥147.63 | -1% |
| Shanghai United Imaging Healthcare Co 688271 | ¥109.00 | ¥43.60 | -60% |
| Demant A/S DEMANT | kr 276.60 | kr 161.17 | -42% |
Compare Osang Healthcare Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Osang Healthcare Co (036220) overvalued or undervalued?
What is the fair value of 036220?
What is the quality score of 036220?
What is the revenue of Osang Healthcare Co (036220)?
What is the net profit margin of 036220?
Does Osang Healthcare Co pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Osang Healthcare Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.